CNR [CHINA METRO-RURAL] 6-K: (Original Filing)

[MAN SANG INTERNATIONAL (B.V.I.) LIMITED UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENT For the nine months ended December 31, 2009 and 2008 2009 HK$’000 (unaudited) 2008 HK$’000 (unaudited) Revenue 254,244 296,388 Cost of sales (144,241 ) (174,359 ) Gross profit 110,003 122,029 Other income and gains, net 16,652 13,978 Selling and distribution costs] [MAN SANG INTERNATIONAL (B.V.I.) LIMITED By Cheng Chung Hing, Ricky]

By | 2016-03-20T11:25:46+00:00 March 1st, 2010|Categories: Chinese Stocks, CNR, SEC Original|Tags: , , , , , |0 Comments

CNR [CHINA METRO-RURAL] 6-K: MAN SANG INTERNATIONAL (B.V.I.) LIMITED UNAUDITED CONDENSED CONSOLIDATED

[MAN SANG INTERNATIONAL (B.V.I.) LIMITED UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENT For the nine months ended December 31, 2009 and 2008 2009 HK$’000 (unaudited) 2008 HK$’000 (unaudited) Revenue 254,244 296,388 Cost of sales (144,241 ) (174,359 ) Gross profit 110,003 122,029 Other income and gains, net 16,652 13,978 Selling and distribution costs] [MAN SANG INTERNATIONAL (B.V.I.) LIMITED By Cheng Chung Hing, Ricky]

By | 2016-03-20T11:26:51+00:00 March 1st, 2010|Categories: Chinese Stocks, CNR, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]

By | 2016-02-07T17:38:37+00:00 March 1st, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69

[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]

By | 2016-02-07T17:39:08+00:00 March 1st, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar